Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New app could help children with diabetes avoid dangerous blood sugar swings

NCT ID NCT07470905

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested DiaBuddy, a mobile app designed to help children with type 1 diabetes and their families make better decisions about insulin dosing and managing sick days. Twenty-five children aged 5 to 18 used the app for three months. The study found that the app's recommendations matched those of a specialist doctor and that using it was linked to improved blood sugar control and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DiaBuddy mobile app (decision-support tool)
What this could lead to
If successful, this app could help children with type 1 diabetes and their families make safer insulin dosing and sick-day decisions at home, potentially improving blood sugar control and quality of life.
What could go wrong
This is a small pilot study with only 25 children, no control group, and short follow-up. The app's benefits may not hold up in larger, longer trials or in different settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Jul 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed Type 1 Diabetes Mellitus for more than 1 year Age 5 to 18 years Attending pediatric endocrinology outpatient clinic at Regency Center for Diabetes Endocrinology and Research, Kanpur Caregiver willing and able to use a smartphone application Written informed consent from parent or guardian and assent from participant where applicable Exclusion Criteria: * Type 2 diabetes or other forms of diabetes Significant comorbidity is known to independently affect glycemic control No smartphone access in the household Prior use of the DiaBuddy application Incomplete follow-up data at 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes (T1D) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Regency Hospital

    Kanpur, Uttar Pradesh, 208001, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.